MARK MINOR: Open Payments
NPI 1720130107 · HUNTINGDON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 32 payments from 11 companies in 2025. Trend: 2023 $533 · 2024 $259 · 2025 $687
Food & beverage: $687
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $166 |
| Novo Nordisk Inc | 6 | $155 |
| ABBVIE INC. | 4 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $79 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Abbott Laboratories | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Exact Sciences Corporation | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| PFIZER INC. | 1 | $17 |
Products named: Wegovy, MAVYRET, ZEPBOUND, MOUNJARO, CAPLYTA, Auvelity, FREESTYLE LIBRE 3, TRELEGY ELLIPTA.
Industry payments across PA — which companies pay providers there.
